Direct skin delivery of α-MSH enhances tofacitinib- and NB-UVB-induced repigmentation in vitiligo [124,125], and a lower amount of circulating α-MSH has been associated with poor outcomes in the case of melanocyte transplantation [126], suggesting that its supplementation (active synthetic substance named Afamelanotide) might be useful as a combined therapy strategy. The gene discussed is STAMBP; the disease is vitiligo.